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NOX1 loss-of-function genetic variants in patients
with inflammatory bowel disease
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Genetic defects that affect intestinal epithelial barrier function can present with very early-onset inflammatory bowel
disease (VEOIBD). Using whole-genome sequencing, a novel hemizygous defect in NOX1 encoding NAPDH oxidase 1
was identified in a patient with ulcerative colitis-like VEOIBD. Exome screening of 1,878 pediatric patients identified
further sevenmale inflammatory bowel disease (IBD) patientswith rareNOX1mutations. Loss-of-functionwasvalidated
in p.N122H and p.T497A, and to a lesser degree in p.Y470H, p.R287Q, p.I67M, p.Q293R as well as the previously
described p.P330S, and the common NOX1 SNP p.D360N (rs34688635) variant. The missense mutation p.N122H
abrogated reactive oxygen species (ROS) production in cell lines, ex vivo colonic explants, and patient-derived colonic
organoid cultures.Within colonic crypts, NOX1 constitutively generates a high level of ROS in the crypt lumen. Analysis
of 9,513 controls and 11,140 IBD patients of non-Jewish European ancestry did not reveal an association between
p.D360N and IBD. Our data suggest that loss-of-function variants in NOX1 do not cause a Mendelian disorder of high
penetrance but are a context-specific modifier. Our results implicate that variants in NOX1 change brush border ROS
within colonic crypts at the interface between the epithelium and luminal microbes.
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INTRODUCTION
In the gastrointestinal (GI) tract, the epithelium is the primary
barrier separating the high density of microbes in the intestinal
lumen from the immune cells in the lamina propria. Defects in
epithelial barrier function predispose to inflammatory bowel
disease (IBD) in humans and cause intestinal inflammation in
animal models.1,2
Genetic risk variants for IBD in loci linked to genes relevant
for epithelial integrity have been identified by genome-wide
association studies (e.g.,GNA12,HNF4A,MUC19, orXPB1).3,4
In addition, there is an expanding group of monogenic defects
associated with significant functional impact on intestinal
epithelial barrier function.5,6 Defects in intestinal epithelial
guanylcyclase gene GUCY2C or the solute carrier family 9
member 3 (SLC9A3) encoding the sodium hydrogen exchanger
NHE3 cause congenital diarrhea and Crohn’s disease-like
intestinal inflammation inB30% of cases.7,8 Likewise, defects
in IKBKG causing impaired nuclear factor-kB signaling result
in epithelial apoptosis and intestinal inflammation.9 In patients
with TTC7A deficiency, defects in epithelial PI4K and Rho
signaling cause disturbed epithelial polarization leading to
multiple intestinal atresia or very early-onset intestinal
inflammation.10–12
Recently, we reported a common NOX1 missense mutation
associated with ulcerative colitis (UC) in males of Ashkenazi
Jewish ancestry, in addition to a rare NOX1 mutation in a
patient with early onset of intestinal inflammation.13 NOX1 is
the catalytic subunit of superoxide-generating nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase complex 1,
and is comprised of NOX1, p22phox, NOXA1, NOXO1, and
Rac1-GTP.14–16 NOX1 is a close structural homolog of NOX2,
the catalytic subunit of the multimeric NADPH oxidase
complex 2 (NOX2, p22phox, p67phox, p47phox, p40phox, and
Rac2-GTP), the enzyme responsible for the microbicidal
‘‘respiratory burst’’ in phagocytes. However, in contrast to
NOX2, NOX1 is located in the membrane of the intestinal
epithelial cells17–21 and, may have additional functions in
endothelial cells and in non-GI epithelium.22
Here we investigate several loss-of-function missense
variants in NOX1 that were identified by whole-genome
and whole-exome sequencing in patients with very early-onset
IBD (VEOIBD).We identified eight males with six hemizygous
non-synonymous NOX1 variants, with variable functional
impact upon reactive oxygen species (ROS) production as
compared to the previously described p.P330S and the common
p.D360N (rs34688635) variants. We identified two variants
with nearly complete loss of function and a further four variants
with reduced activity. Primary patient-derived intestinal
colonic organoids of the loss-of-function variant p.N122H
were used to validate those findings.
RESULTS
Index patient
We studied a male patient of Caucasian origin who presented
with bloody stools and failure to thrive at the age of 2 years
(Table 1). He was diagnosed with IBD at the age of 5 years. His
disease progressed from proctitis to pancolitis at the age of 8
years without upper GI involvement (Figure 1a). Histological
examination of colonic specimens showed crypt architectural
distortion, cryptitis, and crypt abscess formation (Figure 1a).
Histologic assessment of epithelial cell proliferation or goblet
cell formation did not reveal marked differences compared to
inflammatory controls (Supplementary Figure S1 online). The
patient required oral corticosteroid therapy at diagnosis,
followed by thiopurine and then methotrexate therapy.
After years of poorly controlled inflammation, mucosal
healing was achieved with anti-tumor necrosis factor
therapy (adalimumab). Nine years after diagnosis, his
disease was complicated by Epstein–Barr virus-associated
hemophagocytic lymphohistiocytosis whilst on azathioprine
therapy, requiring intensive care therapy. Mutations in XIAP
and SAP were excluded at that time. There was no family
history of IBD.
Whole-genome sequencing of the patient led to the
identification of a novel hemizygous variant in the NADPH
oxidase 1 NOX1; NM_007052; c.A364C; p.N122H
(Supplementary Figure S2). The mutation was validated
with Sanger sequencing and inherited in an X-linked manner
from the patient’s mother (Figure 1b). The mutation is not
present in 1,678 Crohn’s disease (CD), 1,089 UC patients, or
1,862 non-IBD controls, or in any public exome database
covering an excess of 120,000 human alleles (e.g., 1000
Genomes and Exome Aggregation Consortium (ExAC)),
thus supporting the view that this is an extremely rare
genetic variant (Supplementary Table 1). The amino acid
N122 is located in the third transmembrane domain and is
evolutionary highly conserved across species (Figure 1c). In
silico analysis by several tools, including SIFT, PolyPhen-2, and
CADD,23 predicted that the mutation causes a loss-of-function
(Supplementary Table 2). Furthermore, the p.N122H variant
affects all known isoforms of NOX1 (Figure 1d). Other
hemizygous, homozygous, or compound heterozygous variants
in the index patient were considered unlikely pathogenic
(Supplementary Table 3). None of these variants have been
described as causative for IBD or Epstein–Barr virus-induced
hemophagocytosis.
NOX1 expression and epithelial-derived ROS
To understand the relative distribution of ROS-generating
NADPH oxidases in the human GI tract and to compare non-
inflamed homeostasis with inflammatory conditions, we
determined the mRNA expression pattern of several NADPH
oxidases and their subunits. Consistent with previous litera-
ture,17–20 NOX1 is highly expressed in the colonic epithelium
with a gradient from ileum to the distal colon (Figure 1e). The
subunits NOXA1 and NOXO1 are constitutively expressed
along the human GI tract (Figure 1e). Whereas phagocytic
NOX2 can be detected even in the non-inflamed mucosa, we
observed no expression of NOX4 and very low expression of
NOX5 (Supplementary Figure S3a). In parallel with theNOX1
expression gradient, we found increased ROS generation in
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ex vivo biopsies obtained from lower compared to the upper GI
tract suggesting that NOX1 is the primary source of superoxide
in the non-inflamed colonic epithelium (Supplementary
Figure S3b,c).
We visualized superoxide production of colonic crypts
ex vivo using nitroblue tetrazolium chloride. Reaction of
nitroblue tetrazolium chloride with superoxide results in
formation of water-insoluble blue formazan precipitates,
Table 1 Clinical characterization of male patients with non-synonymous NOX1 hemizygous variants
Patient
ID
NOX1
variants
Gender Age of
diagnosis
(of symp-
toms) in
years
Diagnosis
Paris
class.62
Family
history
for IBD
Intestinal and extra-intestinal
symptoms/findings on
examination (age in years)
Histology Treatment for
IBD
P1 c.A364C
p.N122H
M 5 (2) IBDU; E4 Negative Presented with bloody stools
and failure to thrive (2), pro-
gression from proctitis (5) to
pancolitis (19), terminal ileum
normal, perianal skin tags, EBV-
associated HLH (14) whilst on
AZA
Cryptits, crypt architectural
distortion, crypt abscesses,
focal Paneth cell metaplasia,
single micro-granuloma
Oral CS, ASA,
AZA, MTX,
ADA
P2 c.T1408C
p.Y470H
M 9.7 CD; L3L4a,
B1
Negative Initially presented with weight
loss and rectal bleeding
Granulomata, neutrophilic infil-
tration into crypts and surface
epithelium
Oral CS, IFX,
MTX
P3 c.C201G
p.I67M
M 8.6 (7.8) UC; E4 Mother
(UC)
Presented with abdominal pain
and alternating formed stool/
diarrhea with blood/mucous
(7.8). At diagnosis microscopic
pancolitis (8.6), later macro-
scopic disease in rectosigmoid
(17.5), no EIMs
Neutrophil infiltrate, (peri-)
cryptitis, branching, and focal
dropout of glands, regenera-
tion. No granuloma
5-ASA
P4 c.G860A
p.R287Q
M 9.9 (9.5) CD; L3L4a,
B1p
Brother
and aunt
(CD)
Presented with abdominal pain
and loose stools (9.9), right
colon and ileal disease distri-
bution (13), perianal skin tags
and fistula (15.8)
Granulomata, focal branching,
(peri-) cryptitis, intraepithelial
lymphocytes, lymphoplasma-
cytic infiltrate, basal cell
hyperplasia
5-ASA, SALZ,
AB
P5 c.G860A
p.R287Q
M 10.5 (8.5) CD;
L3L4ab;
B2p
Brother
and aunt
(CD)
Presented with long-standing
abdominal pain, variably loose
stools/constipation (8.5), and
more recent periodic blood PR
(10.3). Diagnostic scope pri-
marily small bowel disease and
minor colonic involvement;
perianal fistula (10.5)
Cryptitis, pericryptitis, crypt
distortion, cell infiltrate, giant
cells. No granulomas
5-ASA, AB,
IFX, CS, NUT,
ADA.
Ileocecal
resection for
stricture (12.8),
second ileoce-
cal resection
(15.6)
P6 c.G860A
p.R287Q
M 5.7 (5.3) UC; E2 Cousins
(CD or
UC)
Presented with rectal bleeding
(5.3). At scope, diagnosed with
left sided colitis (5.7). No GI Sx
since age 9 years old. At 15
years old, diagnosed with stage
IVBnon-bulk nodular sclerosing
Hodgkin’s disease. In remission
following therapy
Chronic inflammatory infiltrate Previously
SALZ. Cur-
rently on no
therapy
P7 c. A878G
p.Q293R
M 9.7 (9.4) CD; L2L4a Negative Presentedwith bloody diarrhea,
arthralgia, lethargy, and weight
loss (9.4). Pancolitis at diag-
nosis (9.7), upper GI inflam-
mation (17.5), arthralgias
Cryptitis, crypt abscesses,
Paneth cell metaplasia, apop-
totic epithelial cells involving
most colonic crypts, transe-
pithelial inflammation, No
granulomas.
AB, IV and oral
CS, SALZ,
MTX, IFX
P8 c.A1489G
p.T497A
M 7.1 (7.0) UC; E4 Negative Bloody diarrhea (7.0), diag-
nosed with pancolitis (7.1).
Single episode of pancreatitis
(13.3). In clinical remission since
age 13.3
Focal cryptitis, crypt
abscesses, moderate archi-
tectural distortion, Paneth cell
metaplasia
5-ASA, SALZ,
CS
Abbreviations: AB, oral or intravenous antibiotics given for treatment of colitis, bowel decontamination, and fistula treatment; ADA, adalimumab; 5-ASA, 5-aminosalicylic acid;
AZA, azathioprine; CD, Crohn’s disease; CS, corticosteroids; EBV, Epstein–Barr virus; EIMs, extra-intestinal manifestations; F, female; HLH, hemophagocytic
lymphohistiocytosis; IBDU, IBD unclassified; IFX, infliximab; M, male; MTX, methotrexate; NUT, polymeric/elemental diet; PR, per rectum; SALZ, sulfasalazine; UC, ulcerative
colitis.
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Figure 1 Clinical phenotype of the NOX1 p.N122H patient and NOX1 contribution to baseline reactive oxygen species (ROS) within colonic crypts.
(a)Endoscopy and histology fromNOX1mutant patient. Colonoscopy shows loss of vascular pattern, ulceration, and luminal bleeding (left). Hematoxylin
and eosin stain of colonic biopsies shows crypt architectural distortion and dense inflammatory cell infiltrate in the lamina propria (scale bar¼50 mm,
middle). Magnification of NOX1mutant epithelial crypt demonstrates elongated nuclei (black arrow head) and crypt abscesses (white arrow head, right).
(b) Family pedigree and Sanger sequencing of NOX1 gene around the mutation site in a wild-type control and family members. (c) NOX1 protein
sequence alignment of different genera showing the evolutionary-conserved asparagine at position 122. (d) The NOX1 variant p.N122H affects all three
isoforms of NOX1. Amino-acid sequence was aligned using ClustalW. (e) Analysis of NOX1, NOXA1, and NOXO1 expression by quantitative PCR in
biopsies of the gastrointestinal tract. Single biopsies per segment were obtained from four to seven non-inflamed individuals. Bars represent mean.
Statistical significance was determined by Mann–Whitney U-test. (f) Ex vivo colonic biopsies (within 90min of collection) were incubated with nitroblue
tetrazolium (NBT) in phosphate-buffered saline-glucose at room temperature. Biopsy specimenswere analyzed using lightmicroscopy immediately after
60min NBT incubation (top left, biopsy overview showing dark crypts containing reduced formazan; bottom, ring-like deposition of formazan at epithelial
margin of crypts; top right, single colonic epithelial crypt captured longitudinally at highmagnification). (g)Microscopy of ROS-producing epithelial cells in
colonic crypts of ex vivo biopsies detected byNBT dye ( 200magnification). After 60min of incubation a ring-like deposition of formazan at the epithelial
margin of crypts was evident. In indicated conditions biopsies were co-incubated with either a NOX1 inhibitor (ML171) or a non-specific NAPDH oxidase
inhibitor (diphenyleneiodonium; DPI), to verify the signal. (h, left) DPI or ML171 inhibit superoxide generation and L-012-enhanced chemiluminescence
on colonic biopsy specimens ex vivo. Following the detection of superoxide at baseline, DPI, ML171, or vehicle were added (black arrow) and
chemiluminescencewas recorded over 60min. For each biopsy light emissionwas normalized to baseline reading. Data representmean of nine biopsies
per condition obtained from five non-inflamed controls. (h, right) Results of kinetic assay calculated as area under the curve per patient. Statistical
significance was determined by Mann–Whitney U-test.
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which can be observed by light microscopy (Figure 1f).
Following 60min incubation, we observed the deposition of
formazan at the outer margin of colonic crypts indicating
the constitutive release of superoxide from the colonic
epithelium into the crypt lumen (Figure 1f). Co-incubation
with ML171 (ref. 24) or diphenyleneiodonium (DPI), both
NADPH oxidase inhibitors, suggested a reduction of super-
oxide production (Figure 1g). This finding was confirmed by
the luminescence assay (Figure 1h).
Ex vivo NOX1 biopsy and primary organoids
To assess the functional consequences of p.N122Hmutation on
colonic epithelial ROS production, we first assessed superoxide
release in ex vivo colonic biopsies from the index patient and
compared those to biopsies from patients with IBD and non-
inflamed controls. Although biopsies from the NOX1 p.N122H
variant patient generated low level of superoxide, this was
within the range seen in other patients with quiescent IBD and
non-inflamed controls (Figure 2a). However, as phagocytes
that express NOX2 are present in non-inflamed biopsies
(Supplementary Figure S3a) and lamina propria infiltrating
phagocytes likely contribute to ROS measurements in IBD
patient biopsies, the assay specificity is limited and an epithelial
NOX1 defect is potentially masked.
NOX1 p.N122H reduces ROS production in primary
organoids
To validate the functional impact of the genetic defect in
epithelial cells, we generated primary epithelial organoids from
colonic biopsy specimens of the NOX1 p.N122H patient, a male
IBD control patient, and a healthy female control without IBD
(Figure 2b). Both IBD patients were in clinical remission at the
time of the endoscopy.Colonic organoids expressNOX1mRNA,
along with its subunitsNOXA1 andNOXO1, and this expression
did not differ between the index p.N122H patient and the IBD
control patient (Figure 2c). We found high DUOX2 mRNA
expression but only minimal NOX2 expression in the colonic
epithelial organoids reflecting the epithelial origin and the
absence of phagocytes (Supplementary Figure S3a).
Colonic epithelial organoid cells carrying NOX1 p.N122H
mutation produced significantly less constitutive superoxide
than control organoid cells derived from the IBD patient or a
patient without inflammatory disease (Figure 2d). Of note,
whereas phorbol 12-myristate 13-acetate (PMA) stimulation
increased superoxide generation by control organoids, PMA
stimulation of NOX1 p.N122H organoids did not. Even after
stimulation with PMA, superoxide production by NOX1
p.N122H organoids was significantly less than baseline ROS
of IBD control organoids (Figure 2d).
Functional characterization of multiple NOX1 hemizygous
variants in VEOIBD
To find additional NOX1 variants in patients with VEOIBD we
screened exomes of 1,878 pediatric IBD patients. We identified 5
additional non-synonymousvariants inNOX1 in separatepatients
in whom no other known or plausible genetic monogenic
diagnosis was established (Table 1). The missense variants were
predicted to be damaging by SIFT, PolyPhen-2, or CADD scores,
and were rare (minor allele frequency o1%) genetic variants
(Supplementary Tables 1 and 2). All variants changed conserved
amino acids (Supplementary Figure S4) and were found in
regions with significant homology between NOX1 and NOX2
(Supplementary Figure S5).
To characterize the functional impact of those variants we
transfected the multimeric NADPH oxidase complex 1 in the
colonic epithelial cell line HCT116. Alongside the rare NOX1
variants p.N122H, p.I67M, p.R287Q, p.Q293R, p.Y470H, and
p.T497A that we identified in this study, we tested the
previously described p.P330S variant13 and the common
polymorphism p.D360N (allele frequency European-non-
Finnish, 2.4%). Three variants in patients P14, P15, and
P16 affected potential splice sites, which we could not assess
functionally (Supplementary Tables 1, 2, and 4). We used
HCT116 cells as these cells express only low levels of NOX1
subunits (data not shown) and endogenous ROS generation
cannot be detected (Figure 3a). Co-expression of wild-type
NOX1 together with the subunitsNOXA1 andNOXO1 resulted
in superoxide generation in unstimulated and PMA-stimulated
condition (Figure 3a,b). In contrast, co-expression withNOX1
variants variably diminished ROS generation. Whereas NOX1
variants p.N122H (index patient) and p.T497A completely
abrogated both spontaneous and PMA-induced ROS
production, the NOX1 variants p.I67M, p.R287Q, p.Q293R,
p.P330S, p.D360N (common polymorphism), or p.Y470H were
observed to either decrease spontaneous ROS and/or diminish
PMA-stimulated ROS (Figure 3a,b). Expression levels of wild-
type and variant NOX1 constructs were comparable (data not
shown). This suggests that the rare genetic variants affected the
ROS production to a variable degree between complete loss-of-
function and moderate reduction comparable to polymorphisms.
Characteristics of patients with loss-of-function NOX1
variants
We analyzed the IBD phenotype in all male patients with con-
firmed loss-of-functionNOX1 variants (Table 1 and Supplemen-
taryTable 4).Out of the 10malepatientswith hemizygousNOX1
mutations, 4 presented with CD, 3 with UC, and 3 with IBD
unclassified. In congruency with NOX1 expression, disease loca-
tion was always colonic, with two patients also having perianal
disease. Median age of onset was 7.9 years (range 1.8–10.5 years).
Medical treatment included corticosteroids, aminosalicylates,
azathioprine, methotrexate, or anti-tumor necrosis factor
(infliximab or adalimumab in 4 of 8 patients) and 1 patient
underwent ileocecal resection for stricture. No infections with
intestinal pathogens were recorded. With exception of the index
patient, no other severe hemophagocytic lymphohistiocytosis /
Epstein–Barr virus-driven pathologies were recorded.
Population-based characteristics of genetic loss-of-
function NOX1 variants
In addition to those rare variants in NOX1, common
polymorphisms might similarly contribute to IBD suscept-
ibility. Of note, the common NOX1 polymorphism p.D360N
has recently been associated with UC in Ashkenazi Jewish
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males.13 To determine whether this is Ashkenazi Jewish-
specific or an association across several populations, we
performed a genetic analysis of individuals of non-Jewish
European ancestry. Although we observed a trend in the US
European ancestry cohort (Table 2; Supplementary Tables 5
and 6), neither analysis of allele counts in UK cohorts nor
analysis of summed allele counts from a total of 9,513 healthy
controls and 11,140 IBD patients revealed an association
(Table 2). This suggests that the association of NOX1 p.D360N
with UC in males is not present across different populations.
Variation is also reflected by a variable distribution of p.D360N
allele frequency across populations (Figure 4a).
To further understand the importance ofNOX1 variation, we
compared the frequency of hemizygous NOX1 missense and
NOX1 loss-of-function variants (STOP codon, frameshift, and
predicted splice site), with those inNOX2, the causative gene of
most patients with chronic granulomatous disease. The
frequency of genetic missense variation in NOX1 is higher
as compared to the homologous NOX2 (Figure 4b). Similarly,
the constraint metric based on the ExAC data set indicates that
loss-of-function variants in NOX1 are tolerated as indicated
by a probability of being loss-of-function intolerant25 of 0
(Figure 4c). In contrast NOX2 is extremely intolerant to any
loss-of-function variation (probability of loss-of-function
intolerant 0.998)25 as are many other genes causing X-linked
primary immunodeficiencies (Figure 4c). This suggests that
NOX1 underwent less evolutionary pressure as compared to
NOX2 or other X-linked immunodeficiency genes.
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Figure 3 Comparative analysis of NOX1 variants. (a, b) Generation of superoxide in colonic epithelial cell line HCT116 reconstituted with multimeric
NADPH oxidase complex and expressing wild-type or variant NOX1. ROS was analyzed by L-012-enhanced chemiluminescence in the absence (a) or
presence of phorbol 12-myristate 13-acetate (PMA) (b). Chemiluminescence was measured 48 h post transfection and recorded over 60min. Results
represent eight independent experimentswith 3–4 replicates.Eachdot representsone replicate. Experimentswerenormalized tomean relative light units
(RLUs) without PMA. Line represents mean. Statistical significance was determined with analysis of variance and post-test correction performed with
Dunnett (multiple comparisons to one single control).
Figure 2 NOX1 p.N122H diminishes epithelial reactive oxygen species in primary organoids. (a) Superoxide generation of colonic epithelial biopsies
measured over 60min by L-012-enhanced chemiluminescence and total light emission quantified by area under the curve (AUC). Results are derived
from 17 patients with colonic Crohn’s disease (active disease n¼ 10), 11 patients with ulcerative colitis (active disease n¼ 6), 16 non-inflamed controls,
and the patient with NOX1 p.N122H mutation. One symbol represents the mean of 1–3 pan-colonic biopsy specimens (both right- and left-sided) per
patient. Active vs. quiescent disease dichotomized according to composite assessment, including endoscopic appearance (mucosal ulceration, loss of
vascular pattern, and bleeding), biomarkers (C-reactive protein (CRP)), and histology (density of inflammatory infiltrate, cryptitis, and crypt abscesses).
Statistical significance was determined by Mann–Whitney U test. (b) Organoids from patient with NOX1 mutation p.N122H and inflammatory bowel
disease (IBD) control patient were generated from colonic biopsies obtained during quiescent disease state. Representative images of endoscopy,
histology (hematoxylin and eosin staining, scale bar¼ 50mm), and organoids are displayed. (c) Analysis of NADPH oxidases and certain subunits by
quantitative PCR in NOX1 p.N122H patient and IBD control organoids. (d) Kinetic assay of phorbol 12-myristate 13-acetate (PMA)-activated L-012-
enhanced chemiluminescence on NOX1 p.N122Hmutant, IBD control, and non-inflamed control organoid cells. Relative light units weremeasured over
60min. Results are representative of two independent experiments measured in replicates. Statistical significance was determined byWilcoxon signed-
rank test comparing the AUC.
Table 2 Population genetics of p.D360N variant
Gender Ancestry Group N MAF
(%)
P-value, cases vs.
controls
OR
Male European Control 4,744 2.66
IBD 5,549 2.74 0.843 1.03
UC 2,462 3.45 0.068 1.31
CD 2,895 2.18 0.217 0.82
Ashkenazi
Jewish13
Control 1,708 0.82
UC 297 3.37 1.25 10 3 4.22
Female European Control 4,769 2.44
IBD 5,587 2.77 0.149 1.14
UC 2,263 3.05 0.041 1.26
CD 3,138 2.50 0.857 1.02
Ashkenazi
Jewish13
Control 906 0.99
UC 262 1.53 0.343 1.55
Abbreviations: CD, Crohn’s disease; IBD, inflammatory bowel disease; MAF, minor
allele frequency; OR, odds ratio; UC, ulcerative colitis.
P-values were determined by the ALLELIC test or Fisher’s exact method.13
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In summary, our data suggest that NOX1 is the key NADPH
oxidase for baseline ROS in human colonic crypt epithelium.
Complete loss-of-function variants in NOX1 are rare and not
associated with a distinct IBD sub-phenotype. Population
statistics suggest that loss-of-function variants inNOX1 are rare
but likely tolerated.
DISCUSSION
In this study we investigated rare X-linked variants inNOX1 in
eight male IBD patients. Functional analysis suggests a variant-
dependent loss of NOX1-mediated superoxide generation. The
clinical phenotype of affected patients was early onset of IBD
with progressive and severe colonic disease, refractory to
conventional therapy. The affected cohort demonstrates that
NOX1-dependent ROS production is essential for superoxide
production in colonic crypts.
Our characterization of six rare variants in NOX1 (p.I67M,
p.N122H, p.R287Q, p.Q293R, p.Y470H, and p.T497A) expands
the recent description of the rareNOX1 variant p.P330S and the
commonNOX1polymorphism p.D360N in twomaleVEOIBD
patients.13 Furthermore, the NOX1 variant p.R287Q, which is
functionally characterized in this study, has also been described
but not characterized in an independent cohort of childrenwith
VEOIBD, adding further weight to the significance of epithelial
NOX1.26
Diverse mechanisms maintain intestinal epithelial integrity,
which serves as a critical barrier to luminal bacteria, viruses, and
fungi.1,2 Amongst these, NOX1 is likely to have a relevant
role.27,28 The generation of superoxide by NOX1 at the colonic
epithelial border may have an anti-adhesive or anti-invasive
effect on bacteria, contributing to the barrier function of the
inner mucus layer within colonic crypts. Indeed, our data
confirm previous findings that the gene expression of NOX1
follows the density of bacterial colonization in the GI tract.17–20
Reduced generation of superoxide due to genetic variants in
NOX1may affect crypt homeostasis allowing subsequent crypt
colonization by luminal microbiota. NOX1-derived superoxide
also influences intestinal epithelial differentiation and goblet
cell function.29–31 Colonic mucus produced by goblet cells
provides an important barrier between the intestinal micro-
biota and the colonic epithelium, maintaining sterility at the
epithelial border.32
The importance of NADPH oxidases for barrier function is
also exemplified by DUOX2, an NADPH oxidase family
member, which is expressed throughout the GI tract. Notably,
defects in DUOX2 have been recently described as a potential
susceptibility factor in patients with VEOIBD.13,33 In animal
models, defects in the Drosophila duox2 homolog or in
Zebrafish increased susceptibility against enteropathogens.34,35
Whereas Duoxa / mice on thyroid hormone replacement
showed normal growth and no evident phenotype,36 recent
studies suggested that colonization of segmented filamentous
bacteria in the ileum, bacterial translocation into mesenteric
lymph nodes, and Salmonella typhimurium systemic dissemi-
nation, is dependent on DUOX activity.37 Although DUOX2
expression is inducible and is increased in patients with
intestinal inflammation33,38 thereby potentially contributing to
epithelial stress and intestinal tissue damage, these data indicate
that DUOX activity may a functional mechanism that restricts
bacterial colonization at the mucosal interface.
Interestingly, NOX1 activity regulates DUOX2 expression in
the intestinal epithelium during Citrobacter rodentium
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Figure 4 NOX1 population frequencies and genetic variation. (a) Allele frequency of NOX1 p.D360N in different populations according to Exome
Aggregation Consortium (ExAC) data and published literature.13 (b) Number of hemizygotes found for a given variant (missense, nonsense, and
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infection.39 Although loss of epithelial Cyba protected against
C. rodentium and Listeriamonocytogenes infection, this is likely
an indirect effect due to the resulting overgrowth of H2O2-
producing lactobacilli.39 This suggests an unexpected level of
functional hierarchy and complex collaboration between
NOX1 and DUOX2.39
Despite the complete loss of brush border ROS that has been
observed in two NOX1 variants (p.N122H and p.T497A), we
have not observed an increased susceptibility to intestinal
infections such as Salmonella or Yersinia. This is in agreement
with recent data suggesting that lack of Nox1 does not affect
infection susceptibility in a mouse model of Salmonella
typhimurium-induced typhlitis.40 Nonetheless, larger patient
numbers with complete loss-of-function NOX1 variants are
required to more definitively determine the impact of these
mutations on susceptibility to infection. Interestingly, the
patient with the p.N122H mutation developed severe hemo-
phagocytic lymphohistiocytosis in the context of Epstein–Barr
virus infection whilst on azathioprine therapy.41 Viral spread-
ing has been shown to be increased in Nox1-deficient mice
infected with influenza virus,42 implicating a role for NOX1 in
viral control. Again, larger patient numbers are required to fully
understand the penetrance of the NOX1 variant phenotype.
Given the relatively high load of non-synonymousmutations
of NOX1 compared to NOX2 and the large number of DUOX2
mutations in humans, it is likely that NOX/DUOX enzymes
have partially redundant functions. It is therefore likely that
both NOX1 and DUOX2 have a role in susceptibility to
intestinal inflammation, and loss-of-function variants alone
cause not highly penetrant Mendelian-type disorders. In
keeping with a second hit hypothesis, Nox1 deficiency in
interleukin-10-deficient mice resulted in earlier and more
severe intestinal pathology, but loss of Nox1 alone did not cause
intestinal inflammation.30 Similarly, patients with congenital
secretory diarrhea due to activating mutations in the guanylate
cyclase C (GC-C)7,43 or inactivating mutations in SLC9A3
encoding for the sodium/proton exchanger NHE3,8 a down-
stream target of GC-C, may also present with an IBD
phenotype. In these patients the decreased epithelial uptake
of sodium results in changes of mucosal ion content and pH,
and Nhe3 deficiency in mice leads to an altered composition of
the intestinal microbiota.44,45 This dysbiosis drives intestinal
inflammation in a T-cell-dependent model of intestinal
inflammation.46 Our studies suggest that loss of ROS at the
colonic crypt may have a similar effect on barrier function.
Altogether these data suggest a highly context specific role of
epithelial NADPHoxidases in intestinal homeostasis.Whilst in
some animal models, a lack of interleukin-10 and Nox1
increases epithelial stress and susceptibility to colitis,30 in other
instances, lack of NADPH oxidase activity is protective. Indeed
a protective role of Nox1 and Duox2 is suggested in a mouse
model of ileocolitis caused by lack of protective glutathione
peroxidase factors.47–49 In this model GPx1- and GPx2-
knockout leads to oxidative stress caused by Nox1 and Duox2
with a dominant role of Nox1 for crypt epithelial apoptosis.48,49
This oxidative stress is dependent on the presence of the
intestinalmicrobiota as germ-freemice are protected and colitis
develops within 1 week of bacterial colonization.50 Given the
role ofNOX1 as amodifier of intestinal microbiota, we can only
speculate whether IBD patients with loss-of-function NOX1
variants would benefit from therapeutic microbiome-altering
strategies (e.g., antibiotics, nutrition, probiotics, or fecal
transplant). Further studies characterizing the human gut
microbiota in the setting of NOX1 deficiency are required.
It is possible that the human population genetics reflect this
context specific role of NOX1. Whereas in populations like
Ashkenazi Jews, the hemizygous NOX1 p.D360N variant is
associated with UC, in European descent populations it is not.
Substantially stronger genetic variation of NOX1 compared to
NOX2 suggests that the overall impact on disease susceptibility
of these genes is significantly different despite the high degree of
protein conservation and similarity. It is even possible that the
degree of genetic variation inNOX1 is caused by environmental
factors such as infections where reduced ROS is protective.
In conclusion,we report sixnovel variants in theNOX1 gene in
patients with IBD, two ofwhich are associatedwith complete loss
of function of the gene product and with loss of ROS production.
Our study illustrates the complexity of epithelial barrier function
in the pathogenesis of IBD and the need better to understand the
functional impact of ROS production at the colonic crypt
epithelium as a cause of colonic inflammation.
METHODS
Human subjects. The recruitment of participants was approved by
relevant ethics committees or institutional review boards at the
individual contributing institution. Written informed consent was
obtained from all patients/legal guardians and healthy controls.
Patients with IBD (including the index patient P1) and controls
without intestinal inflammation were prospectively recruited as a part
of the Oxford IBD cohort study or the Oxford Gastrointestinal Illness
Biobank (REC 09/H1204/30 and REC 11/YH/0020). Replication
genotyping of the p.N122H variant was performed in 2,767 IBD
patients and 1,862 non-IBD controls. These individuals were enrolled
by theUK IBDGenetics Consortium (http://www.ibdresearch.co.uk/).
Exomes of 1,878 pediatric-onset IBD patients without genetic
diagnosis were screened for additional rare NOX1 variants. Samples
were previously genotyped as part of the COLORS in IBD study
(n¼ 150; Oxford, UK), the NEOPICS consortium (n¼ 545; Toronto,
ON, Canada; www.neopics.org), or the RISK cohort51 (n¼ 1,183;
Atlanta, GA, USA). Genetic association testing of NOX1 p.D360N
(rs34688635) was conducted on genotype data from IBD patients of
non-JewishEuropean ancestry from the following cohorts: the European
ancestry exome chip data set52 (n¼ 10,523); the Oxford IBD cohort
study (n¼ 513); and the COLORS in IBD study (n¼ 104). Sequence
data fromhealthy individualswere obtained from the European ancestry
exome chip data set52 (n¼ 5,726) and the INTERVAL study (n¼ 4,436;
www.intervalstudy.org.uk). Population controlswere also obtained from
the UK10K project (www.uk10k.org).
Genotyping
Whole-genome sequencing and NOX1 variant p.N122H identification.
The index mutation in NOX1 was identified by whole-genome
sequencing as part of the WGS500 project.53 DNA was analyzed from
peripheral blood mononuclear cells. In summary, whole-genome
sequencing was performed on 3.5–7.5 ng DNA on either the Illumina
HiSeq2000 (Cambridge, UK) or the HiSeq2500 run in standard mode
using v2.5 or v3 sequencing chemistry. The genomic DNA was
fragmented, end-paired, A-tailed, and adapter-ligated before size
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selection and amplification for a multiplexed library preparation as
described in Taylor et al.53 The libraries were paired-end sequenced
and sequenced to an average coverage between 27 and 40 quality reads
per base. Resulting 100 base pair readsweremapped to theGRCh37d5/
hg19 human reference sequence using Stampy and the single-
nucleotide variants and short InDels were called with Platypus.54
Variant files were analyzed using Qiagen’s Ingenuity Variant Analysis
software (www.qiagen.com/Ingenuity; Qiagen Redwood City, CA,
USA). High-quality calls were analyzed. For candidate analysis, we
investigated a gene list of known variants associated with monogenic
forms of IBD.5 Filters for variant frequency (o1%; 1000 Genomes
Project) and predicted deleterious filters (SIFT and PolyPhen) were
applied to prioritize high quality calls for non-synonymous and likely
pathogenic variants.
Replication genotyping of the p.N122H variant. Replication genotyping
on the Sequenom plex was carried out at the Sanger Institute.
Whole-exome sequencing. Regeneron performed whole-exome
sequencing on a cohort of 1,183 probands with pediatric-onset
IBD (ages 0–18.5 years), including their affected and unaffected
parents and siblings, where available (total samples¼ 2,704). Sample
preparation, whole-exome sequencing, and sequence data production
were performed as previously described.55 The exomes of RISK cohort
study participants (n¼ 545) were captured using SureSelect Human
All Exon kit v2 (Agilent Technologies, Oxford, UK), using 3 mg of
genomic DNA. Subsequently, captured libraries were sequenced on
Illumina HiSeq2000 by 100-base pair paired-end sequencing. Image
processing and base calling was performed using standard Illumina
software. Raw sequence reads were mapped relative to the human
genome reference sequence (GRCh38/hg38) using the PEMapper
software tool (Cutler DJ et al., submitted) to identify single-nucleotide
variants.
Sanger sequencing. NOX1 variants were validated using Sanger
sequencing according to the standard techniques.
Histology. Historic routine hematoxylin and eosin histology sections
from the patient identified to harbor the NOX1 p.N122H mutation
and IBD controls were analyzed. Staining of goblet cells or the
proliferation marker Ki67 was performed on archived paraffin-
embedded colonic epithelial biopsies. Specimens were stained using an
Alcian blue and periodic acid-Schiff’s reagent staining kit (Clin-Tech
Limited, Guildford, UK) or rabbit monoclonal antibody to Ki67 (clone
SP66, AbCam, Cambridge, USA), respectively. Nuclear fast red and
hematoxylin (Sigma-Aldrich, Gillingham, UK) were used to coun-
terstain cell nuclei.
Protein sequence alignment. Multiple sequences were aligned using
ClustalW2.56 Data were obtained from the National Center for
Biotechnology Information. Sequence alignment is based on the
following accession numbers: Danio rerio, NP_001095857.1; Xenopus
tropicalis, XP_002939249.2; Gallus gallus, NP_001095300.1; Mus
musculus, NP_757340.1; Homo sapiens, NOX1 isoform 1–3,
NP_008983.2, NP_039249.1, and NP_001258744.1; Homo sapiens,
NOX2, NP_000388.2.
Expression analysis. Colonic biopsies were stored in RNAlater
(Qiagen) before analysis. RNA was extracted using RNAeasy kit
(Qiagen), transcribed in cDNA with High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Waltham, MA), and
expression data were obtained using TaqMan primers (Life Tech-
nologies, Paisley, UK) for NOX 1-5, NOXO1, NOXA1, DUOX1, and
DUOX2. Results were normalized toGAPDH expression. Relative gene
expression was calculated using the DCt method.
Colonic epithelial organoid cultures. Human colon crypts were
isolated and organoids were cultured as previously described.57 Briefly,
crypts were embedded in Cultrex Reduced Growth Factor Basement
Membrane Extract, Type 2 RGF PathClear (Amsbio, Abingdon, UK)
and seeded in 48-well plates. The Basement Membrane Extract was
polymerized for 10min at 37 1C, and 250ml per well of organoid
culture media was added. Organoid culture media consisted of
advanced Dulbecco’s modified eagle medium/F12 supplemented with
penicillin/streptomycin (10mmol l 1), HEPES (1 M), Glutamax
(10mmol l 1), and the following growth factors: Wnt conditioned
media (50%) B27 (1 ), epidermal growth factor (50 ngml 1),
Noggin (10%), R spondin (20%), gastrin (10 nM), nicotinamide
(10mM), A83-01 (500 nM), and SB202190 (10 mM). Y-27632
(10 mmol l 1; Sigma)was included in themedium for the first 5 days in
culture. Once organoid growth was established, the culture media was
refreshed every 3 days.
Transfection of HCT116 cells. The colonic epithelial cell line HCT116
was maintained in McCoy’s 5A Modified (Gibco, Paisley, UK) sup-
plemented with 10% fetal bovine serum. Cell systems were based on
reconstitution of the multimeric NOX1 complex containing NOX1,
NOXO1, and NOXA1 in HCT116 cells. PcDNA3.1-hNox1, pcDNA3.1-
hNoxa1, and pcDNA3.1-hNoxo1 were kind gifts from Botond Banfi &
Karl-HeinzKrause (Addgene,Cambridge,MA,plasmid # 58344, # 58531,
and # 58530).19,58 Mutations were introduced using site-directed
mutagenesis and were verified by sequencing (Eurofins Genomics,
Ebersberg, Germany). HCT116 cells were transfected with Lipofectamine
2000 (Invitrogen, Paisley, UK) following the manufacturer’s instructions.
Expression of wild-type and NOX1 variants was confirmed by quan-
titative PCR. ROS production was analyzed by L-012-enhanced che-
miluminescence 48h post transfection.
ROS assays. ROS generation by colonic epithelial biopsies, organoid
cells, and transiently transfected HCT116 cells was measured using
L-012-enhanced chemiluminescence (Wako Laboratories, Neuss,
Germany). After washing with phosphate-buffered saline, cells or
biopsies were pre-incubated in L-012 (100 mM) for 10min, followed by
stimulation with PMA (5 mgml 1, Sigma) or addition of dipheny-
leneiodonium (DPI, 10 mM, Sigma) and 2-acetylphenothiazine
(ML171, 10 mM, Tocris, Bristol, UK) in indicated conditions. Emission
of light was recorded at baseline and thereafter as a kinetic assay every
1–10min in opaque white 96-well plates (FLUOstar OPTIMA, BMG
Labtech, Aylesbury, UK).
For standardization, all intestinal epithelial biopsies were collected
using Olympus (Southend-on-Sea, UK). Endojaw needle forceps with
a cup-opening size of 7.2mm and analyzed within 90min of collection
with minimal handling. Organoids were trypsinized into single-cell
suspension using TrypLETM express (Gibco), counted, and equal cell
numbers dispensed into white 96-well plates.
For microscopy of ROS-producing epithelial cells, ex vivo colonic
biopsies were incubated with 100mgml 1 nitroblue tetrazolium
chloride (Sigma) in phosphate-buffered saline-glucose (1 g l 1) with
or without NADPH oxidase inhibitors. After 60min incubation,
formation of formazan was analyzed by light microscopy (Carl Zeiss
Axioskop2, Cambridge, UK,  200 magnification) on glass slides
without coverslips. Images were photographed using Q-Imaging
software (Surrey, BC, Canada). Microscopy images were cropped and
analyzed using ImageJ software.59
Disease activity amongst IBD patients was characterized as active or
quiescent on the basis of clinical symptoms (diarrhea, rectal bleeding,
and abdominal pain), endoscopic features (mucosal vascular pattern,
bleeding, or ulceration), histological features (cryptitis and crypt
abscesses, and lamina propria polymorphomuclear cell infiltrate), and
serum biomarkers (C-reactive protein).
Data and statistical analysis. All the data analyses were performed
using GraphPad Prism version 5.02 (GraphPad Software, San Diego,
CA) or R (The Foundation for Statistical Computing, R version 3.2.2,
Vienna, Austria). Unpaired data were compared using Mann–
Whitney U-test and paired data were compared with Wilcoxon
signed-rank test. Significance of differences between multiple groups
was performed with analysis of variance and post-test correction with
Dunnet. Genetic association testing in cases and controls was
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conducted with the ALLELIC test.60 Pooled analyses were performed
on the summed allele counts of different cohorts. P-values ofo0.05
after correction for multiple testing were considered significant.
SUPPLEMENTARYMATERIAL is linked to the online version of the paper
at http://www.nature.com/mi
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